patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_877262 | REC_0007201 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 6.9 | 57 | male | 0 | 23 | 4.4 | 5 | alectinib 600 mg BID | 15.3 | false | MSS | 2026-03-15T05:35:58.619050+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_288625 | REC_0007202 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 19 | 70 | female | 1 | 10 | 5.9 | 1 | sotorasib 960 mg daily | 26.1 | false | MSS | 2026-03-15T05:35:58.619280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_276593 | REC_0007203 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 12.6 | 69 | male | 0 | 20 | 4.9 | 5 | alectinib 600 mg BID | 12.4 | false | MSI-H | 2026-03-15T05:35:58.619574+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_937421 | REC_0007204 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 7 | 68 | female | 1 | 8 | 5.8 | 8 | alectinib 600 mg BID | 16 | false | MSS | 2026-03-15T05:35:58.619806+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_326250 | REC_0007205 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 3.8 | 56 | female | 0 | 18 | 4 | 5 | pembrolizumab 200 mg q3w | 9.6 | true | MSS | 2026-03-15T05:35:58.620037+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_482321 | REC_0007206 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 14.8 | 62 | female | 1 | 15 | 5.3 | 1 | osimertinib 80 mg daily | 16 | false | MSI-H | 2026-03-15T05:35:58.620310+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_363677 | REC_0007207 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 37 | 17.6 | 70 | female | 1 | 12 | 6.7 | 8 | osimertinib 80 mg daily | 12.5 | false | MSS | 2026-03-15T05:35:58.620543+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_938408 | REC_0007208 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 11.5 | 67 | female | 0 | 15 | 4.2 | 9 | sotorasib 960 mg daily | 9.3 | true | MSI-H | 2026-03-15T05:35:58.620775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_192165 | REC_0007209 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 14.5 | 66 | male | 0 | 13 | 6.7 | 1 | entrectinib 600 mg daily | 20.8 | true | MSS | 2026-03-15T05:35:58.621011+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_834721 | REC_0007210 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 14.8 | 69 | female | 0 | 16 | 5.6 | 2 | osimertinib 80 mg daily | 8.8 | false | MSS | 2026-03-15T05:35:58.621244+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_894374 | REC_0007211 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 7.8 | 58 | male | 0 | 22 | 2.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 10.4 | true | MSS | 2026-03-15T05:35:58.621476+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_544720 | REC_0007212 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 19 | 6.3 | 54 | male | 0 | 12 | 5.4 | 5 | pembrolizumab 200 mg q3w | 5.1 | false | MSS | 2026-03-15T05:35:58.621705+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_919929 | REC_0007213 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 9.2 | 79 | female | 2 | 19 | 5 | 1 | osimertinib 80 mg daily | 15 | false | MSS | 2026-03-15T05:35:58.621933+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_636099 | REC_0007214 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 12.5 | 57 | female | 1 | 10 | 6.3 | 1 | sotorasib 960 mg daily | 21.1 | true | MSI-H | 2026-03-15T05:35:58.622166+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_408400 | REC_0007215 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 6.3 | 71 | female | 0 | 5 | 5.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 28.1 | false | MSS | 2026-03-15T05:35:58.622402+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_787618 | REC_0007216 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 31 | 9.4 | 73 | female | 1 | 12 | 5.8 | 1 | sotorasib 960 mg daily | 18.2 | true | MSS | 2026-03-15T05:35:58.622680+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_117576 | REC_0007217 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 10 | 68 | female | 0 | 8 | 5.2 | 5 | sotorasib 960 mg daily | 10.2 | false | MSI-H | 2026-03-15T05:35:58.622916+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_519893 | REC_0007218 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 9.6 | 62 | male | 1 | 13 | 4.9 | 3 | osimertinib 80 mg daily | 13.3 | true | MSS | 2026-03-15T05:35:58.623146+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_754897 | REC_0007219 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 9.9 | 69 | male | 0 | 10 | 6.7 | 7 | sotorasib 960 mg daily | 9.9 | true | MSS | 2026-03-15T05:35:58.623381+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_329223 | REC_0007220 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 7.4 | 74 | female | 1 | 11 | 3.8 | 6 | alectinib 600 mg BID | 9.6 | true | MSS | 2026-03-15T05:35:58.623610+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_460645 | REC_0007221 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 17.8 | 69 | female | 1 | 18 | 6.8 | 5 | osimertinib 80 mg daily | 10.3 | false | MSI-H | 2026-03-15T05:35:58.623846+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_635108 | REC_0007222 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 14.1 | 64 | male | 0 | 19 | 6.6 | 7 | sotorasib 960 mg daily | 6.8 | false | MSS | 2026-03-15T05:35:58.624108+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_519270 | REC_0007223 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 12.3 | 79 | female | 2 | 9 | 4.7 | 2 | entrectinib 600 mg daily | 21.1 | true | MSI-H | 2026-03-15T05:35:58.624344+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_112012 | REC_0007224 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 10.2 | 73 | male | 2 | 20 | 4 | 5 | osimertinib 80 mg daily | 12.5 | true | MSS | 2026-03-15T05:35:58.624582+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_184752 | REC_0007225 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 9.4 | 59 | male | 0 | 21 | 4.7 | 7 | osimertinib 80 mg daily | 12.8 | true | MSS | 2026-03-15T05:35:58.624817+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_947153 | REC_0007226 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 16.2 | 69 | female | 1 | 7 | 7.2 | 2 | osimertinib 80 mg daily | 11.2 | true | MSS | 2026-03-15T05:35:58.625048+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_525540 | REC_0007227 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 16.1 | 56 | female | 0 | 12 | 7 | 2 | osimertinib 80 mg daily | 12.9 | false | MSS | 2026-03-15T05:35:58.625286+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_476383 | REC_0007228 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 9.6 | 54 | female | 0 | 20 | 4.1 | 6 | sotorasib 960 mg daily | 5.8 | true | MSS | 2026-03-15T05:35:58.625515+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_858695 | REC_0007229 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 5 | 65 | female | 0 | 8 | 6.7 | 1 | osimertinib 80 mg daily | 17.2 | true | MSS | 2026-03-15T05:35:58.625791+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_500214 | REC_0007230 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 13.9 | 72 | female | 0 | 14 | 5.7 | 7 | alectinib 600 mg BID | 15.6 | false | MSI-H | 2026-03-15T05:35:58.626030+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_395642 | REC_0007231 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 18.1 | 70 | female | 2 | 19 | 4.1 | 2 | osimertinib 80 mg daily | 22.9 | false | MSS | 2026-03-15T05:35:58.626264+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_435279 | REC_0007232 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 4 | 67 | female | 0 | 53 | 5.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 4.3 | false | MSS | 2026-03-15T05:35:58.626493+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_944568 | REC_0007233 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 9.8 | 73 | female | 1 | 10 | 4.8 | 6 | entrectinib 600 mg daily | 17.7 | false | MSS | 2026-03-15T05:35:58.626722+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_277413 | REC_0007234 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 18 | 10.7 | 62 | female | 1 | 21 | 5.5 | 8 | pembrolizumab 200 mg q3w | 7.8 | false | MSS | 2026-03-15T05:35:58.626957+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_253207 | REC_0007235 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 22 | 8.5 | 63 | female | 1 | 66 | 6 | 1 | pembrolizumab 200 mg q3w | 27.6 | true | MSS | 2026-03-15T05:35:58.627191+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_937346 | REC_0007236 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 26 | 12.3 | 50 | male | 0 | 16 | 4.7 | 0 | osimertinib 80 mg daily | 39.2 | true | MSI-H | 2026-03-15T05:35:58.627425+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_874104 | REC_0007237 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 5.4 | 57 | male | 0 | 18 | 4.4 | 3 | pembrolizumab 200 mg q3w | 14.6 | true | MSS | 2026-03-15T05:35:58.627658+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_411439 | REC_0007238 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 12.4 | 59 | female | 1 | 19 | 6.5 | 4 | carboplatin + paclitaxel + pembrolizumab | 11.2 | false | MSS | 2026-03-15T05:35:58.627893+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_839931 | REC_0007239 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 20 | 6 | 76 | female | 2 | 35 | 5.1 | 7 | pembrolizumab 200 mg q3w | 10.3 | false | MSS | 2026-03-15T05:35:58.628175+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_258844 | REC_0007240 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 31 | 4.6 | 81 | female | 2 | 11 | 4.3 | 1 | sotorasib 960 mg daily | 10.5 | false | MSS | 2026-03-15T05:35:58.628410+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_647199 | REC_0007241 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 5.6 | 71 | female | 0 | 18 | 7.3 | 7 | osimertinib 80 mg daily | 7.7 | false | MSS | 2026-03-15T05:35:58.628652+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_922935 | REC_0007242 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 12.5 | 67 | female | 0 | 11 | 5.1 | 1 | osimertinib 80 mg daily | 6.5 | false | MSS | 2026-03-15T05:35:58.628933+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_270569 | REC_0007243 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 18 | 55 | male | 1 | 15 | 6.7 | 1 | osimertinib 80 mg daily | 5.7 | false | MSS | 2026-03-15T05:35:58.629172+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_733039 | REC_0007244 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 3.4 | 71 | male | 2 | 42 | 6 | 2 | carboplatin + paclitaxel + pembrolizumab | 8.9 | false | MSS | 2026-03-15T05:35:58.629405+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812229 | REC_0007245 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 14.7 | 77 | female | 2 | 12 | 7.6 | 7 | osimertinib 80 mg daily | 7.3 | true | MSI-H | 2026-03-15T05:35:58.629640+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_135454 | REC_0007246 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 24 | 4.2 | 67 | female | 1 | 12 | 3.6 | 0 | carboplatin + paclitaxel + pembrolizumab | 34.8 | false | MSS | 2026-03-15T05:35:58.629867+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_593715 | REC_0007247 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 14.5 | 64 | female | 0 | 12 | 4.1 | 1 | alectinib 600 mg BID | 29 | true | MSS | 2026-03-15T05:35:58.630105+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_741533 | REC_0007248 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 5.7 | 74 | female | 1 | 57 | 5.3 | 5 | pembrolizumab 200 mg q3w | 5.5 | false | MSS | 2026-03-15T05:35:58.630331+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_979554 | REC_0007249 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 10.2 | 71 | female | 3 | 16 | 6.8 | 6 | alectinib 600 mg BID | 7.6 | true | MSS | 2026-03-15T05:35:58.630562+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_652492 | REC_0007250 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 6.6 | 66 | female | 1 | 19 | 3.6 | 3 | alectinib 600 mg BID | 22 | true | MSS | 2026-03-15T05:35:58.630791+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_493482 | REC_0007251 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 16.5 | 64 | female | 1 | 11 | 4.7 | 8 | entrectinib 600 mg daily | 6.6 | true | MSI-H | 2026-03-15T05:35:58.631023+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_887689 | REC_0007252 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 12.4 | 67 | female | 1 | 8 | 4.4 | 2 | osimertinib 80 mg daily | 6.4 | true | MSS | 2026-03-15T05:35:58.631255+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_140330 | REC_0007253 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 11.5 | 61 | female | 1 | 11 | 7.5 | 5 | sotorasib 960 mg daily | 10.8 | false | MSI-H | 2026-03-15T05:35:58.631487+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_945573 | REC_0007254 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 11.2 | 68 | female | 1 | 4 | 7.3 | 5 | alectinib 600 mg BID | 8.3 | true | MSI-H | 2026-03-15T05:35:58.631721+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_479443 | REC_0007255 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 10.5 | 74 | female | 0 | 24 | 5.6 | 5 | osimertinib 80 mg daily | 8.1 | false | MSI-H | 2026-03-15T05:35:58.631999+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_275688 | REC_0007256 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 6.2 | 66 | female | 1 | 10 | 6.6 | 3 | alectinib 600 mg BID | 13.7 | true | MSS | 2026-03-15T05:35:58.632300+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_282046 | REC_0007257 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 5.4 | 71 | female | 1 | 76 | 4 | 1 | carboplatin + paclitaxel + pembrolizumab | 20.6 | true | MSS | 2026-03-15T05:35:58.632532+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_857563 | REC_0007258 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 9.9 | 56 | female | 0 | 14 | 5 | 1 | entrectinib 600 mg daily | 20.4 | false | MSS | 2026-03-15T05:35:58.632765+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_707767 | REC_0007259 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 16.3 | 63 | female | 1 | 14 | 3.3 | 2 | sotorasib 960 mg daily | 29.7 | false | MSI-H | 2026-03-15T05:35:58.633000+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_679234 | REC_0007260 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 7 | 67 | female | 0 | 50 | 7.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 19 | true | MSS | 2026-03-15T05:35:58.633228+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_427277 | REC_0007261 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 32 | 8.3 | 72 | female | 3 | 8 | 2.9 | 1 | osimertinib 80 mg daily | 23.7 | true | MSS | 2026-03-15T05:35:58.633456+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_767033 | REC_0007262 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 4.6 | 67 | male | 0 | 30 | 4 | 6 | sotorasib 960 mg daily | 4 | true | MSS | 2026-03-15T05:35:58.633687+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_833349 | REC_0007263 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 5.7 | 73 | male | 2 | 21 | 6.4 | 6 | sotorasib 960 mg daily | 4.2 | true | MSS | 2026-03-15T05:35:58.633920+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_271513 | REC_0007264 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 14.9 | 59 | male | 1 | 19 | 8.2 | 8 | alectinib 600 mg BID | 17.6 | true | MSI-H | 2026-03-15T05:35:58.634155+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_381431 | REC_0007265 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 32 | 7.2 | 55 | male | 1 | 54 | 3.6 | 2 | pembrolizumab 200 mg q3w | 17.9 | false | MSS | 2026-03-15T05:35:58.634387+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_993141 | REC_0007266 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 10.3 | 70 | female | 0 | 16 | 4.3 | 5 | sotorasib 960 mg daily | 7.2 | false | MSI-H | 2026-03-15T05:35:58.634619+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_248453 | REC_0007267 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 17 | 14.3 | 78 | female | 1 | 11 | 7.8 | 4 | pembrolizumab 200 mg q3w | 8.1 | true | MSS | 2026-03-15T05:35:58.634850+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_637995 | REC_0007268 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 17 | 14.6 | 70 | female | 1 | 11 | 5.8 | 1 | sotorasib 960 mg daily | 9 | true | MSI-H | 2026-03-15T05:35:58.635125+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_209636 | REC_0007269 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 15.8 | 70 | female | 2 | 17 | 6.5 | 4 | osimertinib 80 mg daily | 13.8 | true | MSS | 2026-03-15T05:35:58.635359+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_306266 | REC_0007270 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 7.8 | 71 | male | 1 | 16 | 6.6 | 1 | osimertinib 80 mg daily | 20.6 | true | MSS | 2026-03-15T05:35:58.635592+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_703554 | REC_0007271 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 30 | 10.7 | 70 | female | 2 | 3 | 5.7 | 2 | osimertinib 80 mg daily | 15.1 | true | MSS | 2026-03-15T05:35:58.635825+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_457627 | REC_0007272 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 9 | 61 | male | 0 | 13 | 5.3 | 8 | sotorasib 960 mg daily | 10.1 | true | MSS | 2026-03-15T05:35:58.636055+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_587400 | REC_0007273 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 12.9 | 68 | female | 1 | 13 | 6.1 | 5 | entrectinib 600 mg daily | 16.2 | true | MSS | 2026-03-15T05:35:58.636389+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_388134 | REC_0007274 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 7.2 | 68 | female | 1 | 58 | 2.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 14.3 | false | MSS | 2026-03-15T05:35:58.636619+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_372261 | REC_0007275 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 6.7 | 83 | female | 2 | 37 | 5.9 | 8 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:35:58.636849+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_686584 | REC_0007276 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 9.2 | 57 | female | 0 | 18 | 6.5 | 4 | sotorasib 960 mg daily | 17 | true | MSS | 2026-03-15T05:35:58.637079+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_858938 | REC_0007277 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 8.9 | 81 | female | 2 | 13 | 5.4 | 6 | osimertinib 80 mg daily | 10.1 | true | MSS | 2026-03-15T05:35:58.637308+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_681875 | REC_0007278 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 20 | 12.3 | 77 | male | 1 | 15 | 5.2 | 2 | pembrolizumab 200 mg q3w | 17.4 | false | MSS | 2026-03-15T05:35:58.637542+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_446905 | REC_0007279 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 9 | 72 | female | 2 | 21 | 6.2 | 1 | pembrolizumab 200 mg q3w | 13.1 | false | MSS | 2026-03-15T05:35:58.637771+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_160986 | REC_0007280 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 18 | 8.7 | 59 | female | 1 | 14 | 6.6 | 0 | entrectinib 600 mg daily | 43.7 | false | MSS | 2026-03-15T05:35:58.638002+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_606837 | REC_0007281 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 24 | 12.2 | 81 | female | 3 | 9 | 5.3 | 0 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:35:58.638279+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_593464 | REC_0007282 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 12.9 | 78 | male | 1 | 8 | 4.2 | 8 | sotorasib 960 mg daily | 9.3 | false | MSI-H | 2026-03-15T05:35:58.638517+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_914492 | REC_0007283 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 5.2 | 81 | female | 1 | 15 | 5.2 | 6 | pembrolizumab 200 mg q3w | 6.1 | false | MSS | 2026-03-15T05:35:58.638746+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_278719 | REC_0007284 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 8.2 | 60 | male | 1 | 17 | 6.7 | 1 | pembrolizumab 200 mg q3w | 15.9 | true | MSS | 2026-03-15T05:35:58.638977+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_197117 | REC_0007285 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 13.6 | 66 | female | 1 | 15 | 5.7 | 2 | sotorasib 960 mg daily | 21.4 | false | MSI-H | 2026-03-15T05:35:58.639209+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_605945 | REC_0007286 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 34 | 15.5 | 74 | female | 2 | 3 | 5.4 | 1 | sotorasib 960 mg daily | 21.6 | true | MSS | 2026-03-15T05:35:58.639443+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_971104 | REC_0007287 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 15.9 | 66 | female | 0 | 12 | 6 | 2 | osimertinib 80 mg daily | 25.1 | true | MSI-H | 2026-03-15T05:35:58.639678+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_465481 | REC_0007288 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 13.2 | 69 | male | 1 | 4 | 5.1 | 3 | sotorasib 960 mg daily | 14.5 | false | MSS | 2026-03-15T05:35:58.639912+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_352643 | REC_0007289 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 18.4 | 61 | female | 0 | 10 | 5.8 | 1 | entrectinib 600 mg daily | 27.4 | true | MSS | 2026-03-15T05:35:58.640214+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_685684 | REC_0007290 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 5.3 | 53 | female | 0 | 17 | 6.2 | 5 | osimertinib 80 mg daily | 11.5 | true | MSS | 2026-03-15T05:35:58.640451+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_216771 | REC_0007291 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 11.8 | 78 | female | 1 | 14 | 3.6 | 4 | osimertinib 80 mg daily | 12.2 | true | MSS | 2026-03-15T05:35:58.640684+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_947615 | REC_0007292 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 23 | 11.9 | 68 | female | 0 | 12 | 6.1 | 0 | osimertinib 80 mg daily | 45.1 | true | MSS | 2026-03-15T05:35:58.640917+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_840113 | REC_0007293 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 8.3 | 69 | female | 1 | 60 | 6.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 8.4 | true | MSS | 2026-03-15T05:35:58.641148+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_147095 | REC_0007294 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 17 | 15.3 | 68 | male | 0 | 16 | 5.6 | 2 | osimertinib 80 mg daily | 20.7 | true | MSI-H | 2026-03-15T05:35:58.641430+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_342873 | REC_0007295 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 11.8 | 65 | female | 0 | 23 | 5.7 | 4 | alectinib 600 mg BID | 15.2 | false | MSS | 2026-03-15T05:35:58.641670+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_640178 | REC_0007296 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 6.3 | 69 | female | 1 | 31 | 6.1 | 5 | osimertinib 80 mg daily | 6.7 | false | MSS | 2026-03-15T05:35:58.641902+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_464600 | REC_0007297 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 11 | 13.5 | 48 | female | 0 | 17 | 7.6 | 0 | osimertinib 80 mg daily | 50.3 | true | MSS | 2026-03-15T05:35:58.642136+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_931569 | REC_0007298 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 17 | 8.7 | 67 | female | 1 | 15 | 5.6 | 3 | pembrolizumab 200 mg q3w | 15 | true | MSS | 2026-03-15T05:35:58.642363+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_797272 | REC_0007299 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 17.6 | 68 | female | 0 | 6 | 3.5 | 1 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:35:58.642593+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648867 | REC_0007300 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 12.5 | 79 | female | 2 | 12 | 8.3 | 7 | osimertinib 80 mg daily | 15.1 | false | MSI-H | 2026-03-15T05:35:58.642822+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.